Patents by Inventor Jun-ichi Nezu
Jun-ichi Nezu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150259417Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.Type: ApplicationFiled: May 15, 2015Publication date: September 17, 2015Inventors: Kiyotaka Nakano, Takeshi Yoshino, Jun-Ichi Nezu, Hiroyuki Tsunoda, Tomoyuki Igawa, Hiroko Konishi, Megumi Tanaka, Izumi Sugo, Shigeto Kawai, Takahiro Ishiguro, Yasuko Kinoshita
-
Patent number: 8748128Abstract: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.Type: GrantFiled: April 13, 2010Date of Patent: June 10, 2014Assignees: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose, Akira Tsuji
-
Publication number: 20120220755Abstract: Novel genes significantly homologous to organic cation transporters OCT1 and OCT2 have been successfully isolated by screening a fetal gene library by random sequencing. Proteins encoded by these genes function as transporters of various organic cations.Type: ApplicationFiled: March 14, 2011Publication date: August 30, 2012Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Jun-ichi Nezu, Asuka Oku, Akira Tsuji
-
Patent number: 8242245Abstract: Novel fetal genes (fls353 and fls485) have been successfully isolated from human fetal liver-derived cDNAs. These genes were specifically expressed in tissues including fetal tissues which are thought to contain a large number of undifferentiated cells and actively differentiating/proliferating cells. High levels of expression of these genes were observed also in a variety of cancer cells. The proteins and genes encoding the proteins can be used as the tool for developing drugs for the treatment of tumors.Type: GrantFiled: February 25, 2011Date of Patent: August 14, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose
-
Publication number: 20120129184Abstract: The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.Type: ApplicationFiled: August 3, 2011Publication date: May 24, 2012Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Jun-Ichi Nezu, Akira Tsuji, Asuka Ose
-
Publication number: 20110142843Abstract: Novel fetal genes (fls353 and fls485) have been successfully isolated from human fetal liver-derived cDNAs. These genes were specifically expressed in tissues including fetal tissues which are thought to contain a large number of undifferentiated cells and actively differentiating/proliferating cells. High levels of expression of these genes were observed also in a variety of cancer cells. The proteins and genes encoding the proteins can be used as the tool for developing drugs for the treatment of tumors.Type: ApplicationFiled: February 25, 2011Publication date: June 16, 2011Inventors: Jun-ichi Nezu, Asuka Ose
-
Patent number: 7947470Abstract: Novel genes significantly homologous to organic cation transporters OCT1 and OCT2 have been successfully isolated by screening a fetal gene library by random sequencing. Proteins encoded by these genes function as transporters of various organic cations.Type: GrantFiled: January 21, 2004Date of Patent: May 24, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Oku
-
Patent number: 7919086Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.Type: GrantFiled: July 8, 2005Date of Patent: April 5, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kiyotaka Nakano, Takeshi Yoshino, Jun-Ichi Nezu, Hiroyuki Tsunoda, Tomoyuki Igawa, Hiroko Konishi, Megumi Tanaka, Izumi Sugo, Shigeto Kawai, Takahiro Ishiguro, Yasuko Kinoshita
-
Patent number: 7919604Abstract: Novel fetal genes (fls353 and fls485) have been successfully isolated from human fetal liver-derived cDNAs. These genes were specifically expressed in tissues including fetal tissues which are thought to contain a large number of undifferentiated cells and actively differentiating/proliferating cells. High levels of expression of these genes were observed also in a variety of cancer cells. The proteins and genes encoding the proteins can be used as the tool for developing drugs for the treatment of tumors.Type: GrantFiled: May 8, 2007Date of Patent: April 5, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose
-
Publication number: 20100248359Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.Type: ApplicationFiled: June 9, 2010Publication date: September 30, 2010Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kiyotaka Nakano, Takeshi Yoshino, Jun-Ichi Nezu, Hiroyuki Tsunoda, Tomoyuki Igawa, Hiroko Konishi, Megumi Tanaka, Izumi Sugo, Shigeto Kawai, Takahiro Ishiguro, Yasuko Kinoshita
-
Patent number: 7776329Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.Type: GrantFiled: July 8, 2005Date of Patent: August 17, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kiyotaka Nakano, Takeshi Yoshino, Jun-Ichi Nezu, Hiroyuki Tsunoda, Tomoyuki Igawa, Hiroko Konishi, Megumi Tanaka, Izumi Sugo, Shigeto Kawai, Takahiro Ishiguro, Yasuko Kinoshita
-
Publication number: 20100196960Abstract: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.Type: ApplicationFiled: April 13, 2010Publication date: August 5, 2010Inventors: Jun-Ichi Nezu, Asuka Ose, Akira Tsuji
-
Publication number: 20090220967Abstract: The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.Type: ApplicationFiled: August 18, 2008Publication date: September 3, 2009Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Jun-Ichi Nezu, Akira Tsuji, Asuka Ose
-
Publication number: 20080206750Abstract: Novel fetal genes (fls353 and fls485) have been successfully isolated from human fetal liver-derived cDNAs. These genes were specifically expressed in tissues including fetal tissues which are thought to contain a large number of undifferentiated cells and actively differentiating/proliferating cells. High levels of expression of these genes were observed also in a variety of cancer cells. The proteins and genes encoding the proteins can be used as the tool for developing drugs for the treatment of tumors.Type: ApplicationFiled: May 8, 2007Publication date: August 28, 2008Inventors: Jun-Ichi Nezu, Asuka Ose
-
Patent number: 7413860Abstract: The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.Type: GrantFiled: September 13, 2004Date of Patent: August 19, 2008Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose
-
Publication number: 20070190599Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.Type: ApplicationFiled: July 8, 2005Publication date: August 16, 2007Inventors: Kiyotaka Nakano, Takeshi Yoshino, Jun-Ichi Nezu, Hiroyuki Tsunoda, Tomoyuki Igawa, Hiroko Konishi, Megumi Tanaka, Izumi Sugo, Shigeto Kawai, Takahiro Ishiguro, Yasuko Kinoshita
-
Patent number: 7214774Abstract: Novel fetal genes (fls353 and fls485) have been successfully isolated from human fetal liver-derived cDNAs. These genes were specifically expressed in tissues including fetal tissues which are thought to contain a large number of undifferentiated cells and actively differentiating/proliferating cells. High levels of expression of these genes were observed also in a variety of cancer cells. The proteins and genes encoding the proteins can be used as the tool for developing drugs for the treatment of tumors.Type: GrantFiled: July 14, 2005Date of Patent: May 8, 2007Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose
-
Patent number: 7186536Abstract: A novel gene having the consensus sequence of a serine-threonine kinase active site has been isolated by the suppression subtractive hybridization method which comprised of preparing a library of genes expressed specifically in fetal livers and isolating clones from this library at random. This gene presumably participates in cell growth control because it is highly expressed, especially in actively growing cells, and exhibits a significant homology with a vaccinia virus B1R kinase gene. Thus, it can be utilized as a target for developing cell growth inhibitors or antitumor agents.Type: GrantFiled: May 9, 2003Date of Patent: March 6, 2007Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-ichi Nezu, Asuka Oku
-
Publication number: 20060121523Abstract: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.Type: ApplicationFiled: January 19, 2006Publication date: June 8, 2006Inventors: Jun-Ichi Nezu, Asuka Ose, Akira Tsuji
-
Patent number: 7045316Abstract: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.Type: GrantFiled: March 20, 2002Date of Patent: May 16, 2006Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose, Akira Tsuji